Demographic data in patients with spontaneous deep intracerebral hemorrhage and controls.

<p>Data are expressed as percentage or mean ± SE. Comparisons between controls and SDICH cases were analyzed by χ² test or t-test where appropriate. To convert mg/dL to mmol/L, multiply cholesterol values by 0.02586 and triglycerides by 0.011.</p><p>30-day mRS: modified Rankin scale (mRS) on day 30 after SDICH events.</p><p>SDICH^a: spontaneous deep intracerebral hemorrhage.</p><p>Demographic data in patients with spontaneous deep intracerebral hemorrhage and controls.</p

Differences in hemorrhage size as a function of the presence or absence of <i>MMP-2</i> and <i>TIMP-2</i> minor allele in patients with spontaneous deep intracerebral hemorrhage.

<p>Beta (95% CI) derived from GLM models that included tradition risk factors as independent variables show the per-allelic effect of minor allele in each SNP on hemorrhage size.</p><p>CI^a: confidence interval</p><p>NS^b: non-significant</p><p>Differences in hemorrhage size as a function of the presence or absence of <i>MMP-2</i> and <i>TIMP-2</i> minor allele in patients with spontaneous deep intracerebral hemorrhage.</p

Prior association studies of MMPs/TIMPs with ICH risks.

<p>Prior association studies of MMPs/TIMPs with ICH risks.</p

Clinical characteristics and gene expression levels of the symptomatic HD patients, PreHD carriers and the controls.

<p>HD: Huntington's Disease. SSRI: selective serotonin uptake inhibitor. UHDRS: The Unified Huntington's Disease Rating Scale. Scale ranges (normal to most severe) include motor score (0 to 124), independence score (100 to 10), and functional capacity (13 to 0).</p>‡<p>: <i>P</i> value of ANCOVA with adjustment of age and gender.</p>*<p>: Statistically significant in comparison with controls, <i>P</i><0.05, ANCOVA with <i>post-hoc</i> Bonferroni test;</p>**<p>: Statistically significant in comparison with PreHD and controls respectively, <i>P</i><0.05, ANCOVA with <i>post-hoc</i> Bonferroni test;</p>#<p>: Statistically significant in comparison with HD patients and controls respectively, <i>P</i><0.05, ANOVA.</p

Summarized RT-PCR validation results of the 17 genes in human leukocytes.

*<p>Comparison of the gene expression levels of HD patients (n = 16) with controls (n = 20).</p

Lists of assay ID and probe sequence for RT-PCR.

<p>Lists of assay ID and probe sequence for RT-PCR.</p

Logistic regression models of mt4977 deletion and stroke prognosis.

<p>Logistic regression models of mt4977 deletion and stroke prognosis.</p

Detection of mtDNA⁴⁹⁷⁷ and quantification of total and deleted mtDNA in leukocytes using real-time quantitative PCR.

<p>Detection of mtDNA⁴⁹⁷⁷ and quantification of total and deleted mtDNA in leukocytes using real-time quantitative PCR.</p

Differentially-expressed protein molecules in CSF of Huntington's disease (HD) patients.

a)<p>Spots numbered as shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015809#pone-0015809-g001" target="_blank">Figure 1</a>.</p>b)<p>The accession numbers on SWISS-PROT database.</p>c)<p>The MASCOT search score of identified proteins.</p>d)<p>The percentage of sequence coverage of matched peptides in the identified protein.</p>e)<p>The mean protein expression level in the HD patients over that in the controls in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015809#pone-0015809-g001" target="_blank">Figure 1C</a>.</p>f)<p>The frequency of the target protein, for which the expression ratio of HD/C was >1.5. <i>P</i><0.05 indicates a significant difference in expression levels between HD patients and controls analyzed by paired student's <i>t</i>-test.</p

Comparison of patients with and without the 4977 deletion.

<p>Comparison of patients with and without the 4977 deletion.</p